Curated News
By: NewsRamp Editorial Staff
June 15, 2026
NanoViricides Gains Approval for Ebola Phase II Trial with Oral Gummies
TLDR
- NanoViricides' NV-387 Oral Gummies for ebolavirus is the only oral treatment candidate in clinical testing, offering a competitive edge in outbreak settings.
- The Phase II trial for NV-387 Oral Gummies targets host-cell features, with approvals needed from DRC ethics and regulatory bodies before study initiation.
- An oral Ebola treatment could save lives in resource-limited areas by replacing difficult intravenous therapies, improving outbreak response in the DRC.
- NanoViricides' NV-387 is a broad-spectrum antiviral that also targets mpox, RSV, and COVID, showcasing its versatile therapeutic potential.
Impact - Why it Matters
This news matters because the approval of NV-387 Oral Gummies for a Phase II Ebola trial introduces a potentially game-changing oral treatment for a deadly virus, addressing critical logistical challenges in outbreak zones where IV treatments are impractical. If successful, it could provide a scalable, easy-to-administer therapy for Ebola, saving lives in resource-limited regions and reinforcing NanoViricides’ broad-spectrum antiviral platform against future pandemics.
Summary
In a significant development for Ebola treatment, NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses, making it a unique candidate in the fight against Ebola. According to the company, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, which could revolutionize outbreak response in resource-limited settings where intravenous treatments are challenging to deploy.
NanoViricides said the next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. The company noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale. This approval marks a critical milestone for NanoViricides, as it advances its lead drug candidate NV-387 into human trials for a deadly viral disease.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide technology is based on intellectual property from TheraCour Pharma, Inc. The company has a broad pipeline targeting viruses including RSV, COVID-19, influenza, mpox, and Ebola. NV-387 is also being developed for COVID-19 (as NV-CoV-2) and other respiratory infections. The company’s platform holds potential for treating numerous viral diseases, but as with any drug development, success is not guaranteed. Investors can follow updates in the company’s newsroom at https://nnw.fm/NNVC.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Gains Approval for Ebola Phase II Trial with Oral Gummies
